GAO third drug class report finds little evidence to support pharmacy-only nonprescription drugs.
Executive Summary
THIRD CLASS OF DRUGS NOT SUPPORTED BY AVAILABLE EVIDENCE, GAO STUDY released Aug. 24 concludes. The General Accounting Office conducted an assessment of "the evidence for creating an additional class of drugs in the U.S. that would not be for sale outside pharmacies but would be available without a physician's prescription" at the request of Rep. Dingell (D-Mich.) in 1992. The report concludes that "little evidence supports the establishment of a pharmacy or pharmacist class of drugs in the U.S. at this time."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth